MarketCap
Facebook
X
Telegram
Eli Lilly and Company Market Cap | LLY
As of September 09, 2026 Eli Lilly and Company has a market cap of $ 1.01 T
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Eli Lilly and Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 940 B | 780 B | 665 B | 297 B | 226 B | 182 B | 137 B | 120 B | 90.6 B | 82.2 B | 87.4 B | 80 B | 59.5 B | 62.1 B | 43.7 B | 36 B | 38.1 B | 52.1 B | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 940 B | 36 B | 221 B |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Фармсинтез
LIFE
|
2 B | - | - | - |  Russia |
 |
Ayala Pharmaceuticals
AYLA
|
7.72 M | - | - | $ 7.46 M |  Israel |
 |
Amryt Pharma plc
AMYT
|
2.55 B | - | - | $ 621 M |  Britain |
 |
ASLAN Pharmaceuticals Limited
ASLN
|
427 M | - | -14.27 % | $ 1.7 M |  Singapore |
 |
Revolution Medicines
RVMD
|
19.6 B | $ 207.32 | 0.24 % | $ 39.4 B |  USA |
 |
Rhythm Pharmaceuticals
RYTM
|
6.34 B | $ 101.8 | 0.08 % | $ 6.62 B | USA |
|
Rezolute
RZLT
|
586 M | $ 4.4 | 0.88 % | $ 334 M | USA |
 |
Sana Biotechnology
SANA
|
995 M | $ 3.45 | 0.77 % | $ 874 M | USA |
 |
Seer
SEER
|
123 M | $ 1.95 | 0.26 % | $ 108 M | USA |
 |
Precigen
PGEN
|
970 M | $ 6.87 | 0.14 % | $ 2.15 B | USA |
 |
SIGA Technologies
SIGA
|
404 M | $ 3.2 | 1.86 % | $ 229 M | USA |
 |
Syndax Pharmaceuticals
SNDX
|
1.73 B | $ 19.94 | 0.05 % | $ 1.73 B | USA |
 |
Soligenix
SNGX
|
6.12 M | $ 0.38 | 1.18 % | $ 1.97 M | USA |
 |
Spruce Biosciences
SPRB
|
47.6 M | $ 59.09 | 2.0 % | $ 45.3 M | USA |
 |
Sarepta Therapeutics
SRPT
|
1.64 B | $ 20.94 | 0.04 % | $ 2.1 B | USA |
 |
Stoke Therapeutics
STOK
|
2.01 B | $ 30.05 | 0.81 % | $ 1.78 B | USA |
 |
Sutro Biopharma
STRO
|
181 M | $ 19.1 | 0.34 % | $ 162 M | USA |
 |
Shattuck Labs
STTK
|
349 M | $ 6.5 | 0.29 % | $ 452 M | USA |
 |
Supernus Pharmaceuticals
SUPN
|
3.11 B | $ 42.43 | 0.23 % | $ 2.4 B | USA |
 |
Savara
SVRA
|
1.17 B | $ 5.53 | 2.98 % | $ 1.23 B | USA |
 |
China SXT Pharmaceuticals
SXTC
|
1.14 M | $ 2.24 | 0.45 % | $ 1.52 M |  China |
 |
Takeda Pharmaceutical Company Limited
TAK
|
23.8 B | $ 18.32 | 1.49 % | $ 28.9 B |  Japan |
 |
Bio-Techne Corporation
TECH
|
11.3 B | $ 72.31 | 0.01 % | $ 11.3 B | USA |
 |
Tenax Therapeutics
TENX
|
569 M | $ 1.98 | 2.06 % | $ 77.7 M | USA |
 |
Teva Pharmaceutical Industries Limited
TEVA
|
41.3 B | $ 36.76 | 1.21 % | $ 42.1 B | Israel |
 |
TG Therapeutics
TGTX
|
4.34 B | $ 55.74 | 0.58 % | $ 8.04 B | USA |
 |
Trevi Therapeutics
TRVI
|
1.51 B | $ 16.82 | 1.17 % | $ 2.27 B | USA |
 |
Taysha Gene Therapies
TSHA
|
1.46 B | $ 5.48 | 0.54 % | $ 1.75 B | USA |
 |
Sol-Gel Technologies Ltd.
SLGL
|
203 M | $ 69.37 | 0.35 % | $ 193 M | Israel |
 |
UroGen Pharma Ltd.
URGN
|
924 M | $ 43.82 | 0.02 % | $ 2.11 B | Israel |
 |
United Therapeutics Corporation
UTHR
|
23.6 B | $ 497.97 | 2.12 % | $ 22.1 B | USA |
 |
Spero Therapeutics
SPRO
|
133 M | $ 1.19 | 0.41 % | $ 66.7 M | USA |
 |
Scholar Rock Holding Corporation
SRRK
|
5.09 B | $ 57.42 | 3.78 % | $ 6.59 B | USA |
 |
Jounce Therapeutics
JNCE
|
47.5 M | - | - | $ 98.4 M | USA |
 |
NextCure
NXTC
|
36 M | $ 8.42 | 7.67 % | $ 23.9 M | USA |
 |
Verrica Pharmaceuticals
VRCA
|
66.7 M | $ 5.26 | 0.75 % | $ 56 M | USA |
 |
Viridian Therapeutics
VRDN
|
2.99 B | $ 23.17 | 1.09 % | $ 2.36 B | USA |
 |
Zosano Pharma Corporation
ZSAN
|
52.7 M | - | 7.23 % | $ 2.72 M | USA |
 |
Vertex Pharmaceuticals Incorporated
VRTX
|
125 B | $ 528.9 | 0.22 % | $ 135 B | USA |
 |
Verastem
VSTM
|
404 M | $ 8.08 | 0.55 % | $ 560 M | USA |
 |
vTv Therapeutics
VTVT
|
67.6 M | $ 32.79 | 0.03 % | $ 130 M | USA |
 |
Voyager Therapeutics
VYGR
|
241 M | $ 3.4 | 3.85 % | $ 200 M | USA |
 |
Aravive
ARAV
|
60.4 M | - | -13.39 % | $ 1.45 M | USA |
 |
Wave Life Sciences Ltd.
WVE
|
2.6 B | $ 4.91 | 1.03 % | $ 828 M | Singapore |
 |
Tonix Pharmaceuticals Holding Corp.
TNXP
|
114 M | $ 13.16 | 0.15 % | $ 112 M | USA |
 |
Xenetic Biosciences
XBIO
|
4.37 M | $ 4.28 | 0.86 % | $ 7.28 M | USA |
|
XBiotech
XBIT
|
70.4 M | $ 2.18 | 0.23 % | $ 66.5 M | USA |
 |
Exicure
XCUR
|
29 M | $ 1.41 | 12.8 % | $ 8.88 M | USA |
 |
Xenon Pharmaceuticals
XENE
|
2.38 B | $ 59.55 | 0.18 % | $ 4.72 B |  Canada |
 |
Xeris Pharmaceuticals
XERS
|
967 M | $ 8.48 | 0.12 % | $ 1.36 B | USA |